Cowen analyst Ritu Baral reiterated an Outperform rating on Vera Therapeutics (NASDAQ: VERA).The analyst comments: "VERA's neutralizing mAb against BKV ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE